Is Allergy Testing Required or Available for Cosentyx?
No, allergy testing is not available or required for Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug is administered via subcutaneous injection, and hypersensitivity reactions occur in about 1% of patients, but pre-treatment skin or allergy tests are not part of the prescribing guidelines or clinical protocols.[1][2]
What Hypersensitivity Reactions Have Been Reported?
Clinical trials and post-marketing data show rare severe reactions like anaphylaxis (0.1-1%), angioedema, or urticaria, typically during or shortly after injection. These are managed with standard emergency protocols—stopping the infusion, epinephrine, and supportive care—rather than predictive testing. No validated allergy test (e.g., skin prick or IgE assays) exists for secukinumab.[1][3]
How Do Doctors Screen Patients Before Starting Cosentyx?
Screening focuses on active infections (e.g., TB test), live vaccines, and IBD history, not allergies. Patients with known hypersensitivity to secukinumab or latex (in needle covers) are excluded. Prescribers monitor for reactions at first doses and educate on symptoms like rash or swelling.[1][2]
Can You Develop an Allergy After Starting Treatment?
Yes, delayed hypersensitivity is possible, even after multiple doses. If it occurs, discontinue and consider alternatives like TNF inhibitors. No diagnostic test confirms secukinumab-specific allergy; diagnosis relies on clinical history and rechallenge avoidance.[3]
What Are Patient-Reported Allergy Concerns?
Forum discussions and FDA reports highlight injection-site reactions mistaken for allergies (e.g., redness in 10-20% of users), but true allergies are uncommon. Patients often ask about switching biologics if mild reactions appear.[4]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: Drugs.com - Cosentyx Side Effects
[4]: DrugPatentWatch.com - Cosentyx Patient Reviews